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Identification of cell regulatory genes that drive carcinogenesis
(e.g. oncogenes, tumour suppressor genes and DNA repair genes)
is one of the major goals in cancer research, eventually resulting in
new anticancer drug targets and new therapeutic and diagnostic
approaches. These genes are frequently found to be differentially
expressed between normal and neoplastic tissues, suggesting that
over-expression or loss of expression of these genes will lead to
carcinogenesis (Weinberg, 1996). The Hevin gene was initially
cloned from endothelial cells in lymphoid tissues and is thought to
facilitate lymphocyte migration through the endothelium by
modulating endothelial cell adhesion (Girard and Springer, 1996).
Early evidence suggests that it could be an important regulatory
gene in neoplastic tissues (Bendik et al, 1998; Nelson et al, 1998).
Recently, Hevin expression was shown to be down-regulated in
prostate (Nelson et al, 1998) and non-small-cell lung (Bendik et al,
1998) cancers, suggesting that Hevin may be involved in the
pathogenesis of these cancers. Sequence analysis of the Hevin
gene has revealed that it encodes a secreted, acidic, calcium-
binding protein closely related to the anti-adhesive protein called
SPARC (also known as osteonectin or BM-40; Girard and
Springer, 1995). SPARC and Hevin share 62% identity over a
region of 232 amino acid residues spanning more than four-fifths
of the SPARC coding sequence. Although these two genes are
related structurally and functionally, it is likely that the proteins
have both distinct and overlapping physiological roles. For
example, while Hevin is expressed in many tissues, SPARC
expression is tissue-specific (Girard and Springer, 1996). Previous
evidence indicates that SPARC may function as a negative
regulator of cell proliferation by inhibiting the progression of cells
from G1 to S phase (Funk and Sage, 1991). Support for this
finding was provided in a study using differential display in which
SPARC was identified as a down-regulated transcript in ovarian
carcinoma (Mok et al, 1996). Genes that are negative regulators of
cell proliferation (e.g. tumour suppressor genes) are frequently
down-regulated in cancer tissues (Weinberg, 1995). However,
Hevin expression in cancers other than prostate and lung or its
physiological function in cell growth and differentiation remains
completely unknown. In this paper, we report the molecular
cloning of the human Hevin gene from omental adipose tissues
and demonstrate mismatches with the published sequence. We
have analysed its expression in many normal and neoplastic
tissues and, furthermore, studied for the first time its effect in cell
growth and proliferation.
MATERIALS AND METHODS
Human tissues and preparation of RNA
Pieces of human omental adipose tissue (between 10 and 1000 g,
five patients) were obtained during intra-abdominal surgery and
immediately frozen in dry ice. The patients were men under the
age of 65. Total RNA of the human tissues or cultured HeLa 3S
cells was prepared using Trizol reagent (Life Technologies,
Paisley, UK) as described previously (Kutoh et al, 1998).
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One microgram of RNA was reverse-transcribed (RT) by 500 ng
of the human Hevin reverse primer (sequence shown below; all 
the oligonucleotides used in this work were purchased from
Eurogentec, Seraing, Belgium), 1 ml of 10 mM dNTPs and 200
units of SuperScrip II reverse transcriptase (Life Technologies) in
a total volume of 20 ml according to the manufacturers’ protocol.
After the reaction, the mixture was heated at 65°C for 10 min and
80 ml water was added. Subsequently, polymerase chain reactions
(PCR) reactions were performed in a total volume of 50 ml
containing 3 ml of cDNA, 1 ml of 20 mM each specific human
Hevin primers, 1 ml of 10 mM dNTPs and 2.5 U of Platinum Taq
high fidelity DNA polymerase (Life Technologies).
Forward: AGTGGCTCTGAGTCCAGCCCCTTAC (corres-
ponding to nt 156–180 from the human Hevin sequence;
GenBank/EMBL accession no. X82157). Reverse: CGTTCAA-
AACAAGAGATTTTCATCTATGTC (nt 2170–2195 of X82157)
After an initial denaturation at 93°C for 2 min, PCR was carried
out in 30 cycles (step 1 to step 3) using Gene Amp 9700 (Perkin-
Elmer, Norwalk, CT, USA) as follows:
step 1: 93°C for 1 min (denaturation)
step 2: 61°C for 1 min (annealing)
step 3: 72°C for 2 min (reaction)
step 4: 72°C for 7 min (final elongation).
The amplified product (2040 bps) was ligated into pGEM-T
easy Vector (Promega, Madison, WI, USA) according to the
manufacturer’s protocol. The construct was sequenced on both
strands by using vector primers T7 and Sp6 and insert specific
primers every 300 bp. Sequencing reactions were run on an
Applied Biosystems 377 XL DNA sequencer (Perkin-Elmer). Two
clones termed G1 and G5 having three different amino acid (aa)
sequences at positions 116, 161 and 419 (for sequence, see the
results section) were further prepared by plasmid Maxi kit
(Qiagen, Hilden, Germany). The G5 construct was digested with
EcoRI and the insert containing the full-length Hevin was ligated
into the EcoRI site of the pTRE expression vector (Clontech, Palo
Alto, CA, USA), yielding the clone termed M8. It was further
prepared using EndoFree Maxi kit (Qiagen) for the cell transfec-
tion study.
Expression of Hevin in vitro and molecular weight
determination
Human Hevin protein was expressed in vitro using the two Hevin
clones (G1 and G5) in the TNT T7 quick coupled
transcription/translation system (Promega) in the presence of
35S-methionine (Amersham, Aylesbury, UK) as described previ-
ously (Kutoh et al, 1992). Two microlitres of the translated protein
in reticulocyte lysate were loaded onto an 8.5% sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
(Haeffner et al, 1995). After electrophoresis, the gel was dried
and exposed to X-ray film (Amersham) overnight at room
temperature.
Database analysis
The LifeSeq® v. 4.5 human EST database (Incyte Pharmaceuticals
Inc., Palo Alto, CA, USA) was analysed to provide an indication
of the human Hevin gene expression in various tissues. For each
cDNA library in LifeSeq®, per cent abundance of Hevin
expressed sequence tags (ESTs) was calculated as the fraction of
the number of ESTs matching the Hevin gene over the total
number of ESTs. cDNA libraries containing Hevin ESTs were
subsequently grouped per tissue and disease status (normal,
neoplastic and non-neoplastic diseased). Per cent abundance was
averaged to overcome cDNA library size differences, again per
tissue and disease status. A total of 1367 Hevin ESTs from 361
cDNA libraries were collected for this analysis. Chromosome
location of the Hevin gene was queried on the ‘gene map’ at the
National Center for Biotechnology Information (Bethesda, MD,
http://www.ncbi.nlm.nih.gov/genemap/).
Northern blot analysis
Northern blot nylon membrane containing 2 mg of poly-adenosine
(poly-A) RNA from various human normal and neoplastic
tissues/cells was purchased from Clontech (Multiple Tissue
Northern Blots) and Invitrogen (mRNA REAL Blots, Carlsbad,
CA, USA). The PCR-amplified fragment of the Hevin gene was
purified from agarose gel using agarase (Boehringer Mannheim,
Mannheim, Germany). The purified fragment was radiolabelled
with 32P-dATP using a random primer (Boehringer Mannheim).
Then, 345 bp of the PCR-amplified fragment of glyceraldehyde
phosphate dehydrogenase (GAPDH) (Kutoh et al, 1998) were
used as a control probe. Hybridization of the membrane overnight
at 65°C using Express-Hyb hybridization solution (Clontech) and
washing of the membrane were performed according to the manu-
facturer’s protocol (Clontech). The signals were visualized by
autoradiography using Hyperfilm (Amersham).
Cell culture, transfection and cell proliferation assays
HeLa 3S tet-off cells (Yin et al, 1996) were purchased from
Clontech. The cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies) supplemented with 10%
fetal calf serum in a 75-cm2 flask. Transient transfection of the
Hevin clone in pTRE expression vector (designated M8, see
above) using Lipofectin® (Life Technologies) was performed
according to the manufacturer’s protocol. With this method,
70–90% of the cells were shown to be transfected by using the
b-gal staining method (Sambrook et al, 1989). The cells were
further cultured in the presence of 1 mg ml–1 doxycycline (Dox,
Sigma, St Louis, MO, USA) for 24 h. Then 5000 cells were trans-
ferred (per well) to a 96-multiwell plate and they were further
cultured in the absence of Dox for 16 h. Subsequently, the rate of
cell proliferation was measured by 5-bromo-2¢-deoxyuridine
(BrdU) incorporation (4 h) using Cell Proliferation enzyme-linked
immunosurbent assay (ELISA) BrdU kit (Boehringer Mannheim)
as described previously (Law et al, 1996).
HeLa 3S tet-off cells stably transfected with the Hevin clone
(M8) were created according to the manufacturer’s protocol
(Clontech). Equal numbers of cells (1000–5000) were transferred
(per well) to a 96-multiwell plate and cultured in the absence of
Dox for 48–96 h. The rate of cell proliferation was measured by
the same Cell Proliferation ELISA BrdU kit as mentioned above
(Boehringer Mannheim).
Hevin expression in the cultured HeLa 3S tet-off cells in the
absence or presence of 1 mg ml–1 Dox or in human omental adipose
tissue (HWAT) was verified by RT-PCR using the Hevin-specific
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ELISA assay. Then, 500 ng of the RNA was reverse-transcribed 
by oligo (dT) and the PCR reaction was performed as described
above. The PCR products were loaded on 1.5% agarose 0.5 XTBE
gel and the images of the ethidium bromide-stained gels were
obtained using the Image Master (Pharmacia, Uppsala, Sweden).
The PCR products were verified by sequencing.
Cell cycle analysis
A total of 0.3 ´ 106 cells (stably transfected with Hevin or mock
control) were seeded in 75-cm2 flasks. The cells were cultured for
72 h in the absence of Dox. They were trypsinized (EDTA–
trypsine, Life Technologies) and washed with phosphate-buffered
saline (PBS). The number of cells was counted using Cytoron
(Ortho, Raritan, NJ, USA). The cells were overnight fixed in ice-
cold methanol and DNA staining was performed according to the
method described by Vindelov et al (1983). PI-fluorescence of 
10 000 nuclei was acquired on a FACS Calibur (Becton Dickinson,
San Jose, CA, USA). Cell cycle analysis was done with Modfit
software (Verity, ME, USA).
RESULTS
Full-length cDNA cloning of human Hevin and
sequence analysis
Sequence analysis of the Hevin clone showed an open reading
frame of 1992 nucleotides (nt). The predicted 664-aa Hevin
protein has a calculated molecular weight of Mr 75.2 kDa, with an
isoelectric point of 4.68. There are three nt mismatches with the
published human Hevin sequence (X82157) as assessed by the
database analysis. These are at the nt positions 544 (T/A), 679
(A/G) and 1452 (A/G). Subsequently, they caused three aa changes
at positions 116 (S/T), 161 (E/G) and 419 (T/A) as shown in Table
1. To study the consistency of these mismatches, we cloned the
Hevin gene from five different patients. The mismatches at 116 aa
and 419 aa were consistently found in tissues from five different
patients. The mismatch at 161 aa, however, is controversial: three
subjects had G, but the other two had the same sequence (E) as the
published Hevin protein (Girard and Springer, 1996). We desig-
nated these two clones G1 (161 aa is E) and G5 (161 aa is G).
Hevin was further studied on the translational level. For this
purpose, the two Hevin clones in pGEM-Teasy vector (designated
G1 and G5) were translated in vitro in reticulocyte lysate in the
presence of 35S-methionine, as described in Materials and
Methods. Two major signals of 75 kDa and 150 kDa were obtained
(Figure 1), suggesting that the Hevin protein may form a 150 kDa
homodimer in vitro.
Hevin is widely expressed in normal tissues but is
strongly down-regulated in many cancers
Recent reports have indicated that Hevin expression is down-regu-
lated in prostate cancer (Nelson et al, 1998) and non-small-cell
lung cancer (Bendik et al, 1998). We have therefore addressed the
question of whether this down-regulation is observed in other
types of cancer. In order to answer this question, we first
performed a Hevin expression analysis by a human EST database
as described in Materials and Methods. A total of 1367 ESTs
identical to the Hevin sequence were identified from 361 cDNA
libraries from a wide range of tissues in the LifeSeq EST database
(Incyte Pharmaceuticals). As shown in Figure 2, Hevin ESTs were
found in a wide range of normal and non-neoplastic diseased
tissues. Per cent abundance is especially high in artery, brain, fat,
penis and uterus. However, in neoplastic tissues Hevin ESTs were
found in only some tissues with lower per cent abundance (Figure
2, filled bar). These results suggest that the Hevin gene may be
expressed at a higher level in non-neoplastic tissues (both normal
and diseased) than in neoplastic tissues.
To confirm this database result experimentally, Northern blot
analysis using a radiolabelled human Hevin probe and nylon
membranes containing mRNAs from various human normal and
cancer tissues/cells (Multiple Tissue Northern Blots, Clontech)
was performed. As presented in Figure 3A panel I, a single signal
of 2.8 kbps was constitutively observed with various levels in
human normal tissues. High levels of expression were observed in
heart, brain, skeletal muscle, small intestine and spinal cord. Low
levels of expression were observed in liver and peripheral blood
leucocyte. However, in contrast to this, Hevin expression in cancer
cells was observed only in promyelocytic leukaemia (HL-60) and
Burkitt’s lymphoma (Raji) (Figure 3A, panel I). GAPDH was used
as a control (Figure 3A, panel II).
Hevin: a candidate suppressor gene 1125
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Table 1 Sequence variation of human Hevin amino acids
aa position X82157 G1 G5
116 S T T
161 E E G
419 T A A
G5 G1
150 kDa
75 kDa
Figure 1 Hevin may form a homodimer. Hevin was translated in vitro from
two clones (G1 and G5) in the reticulocyte lysate in the presence of 35S-
methionine as described in Materials and Methods. Two microlitres of the
translated products were analysed by SDS-PAGE followed by
autoradiography. The arrows indicate the molecular size of the translated
products1126 A Claeskens et al
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)We extended this experiment using nylon membranes
containing equal amounts (2 mg) of mRNA from various human
tissues, both normal and cancerous (mRNA REAL Blots,
Invitrogen). The quality of the membrane (RNA integrity, loading
equality) was verified by the manufacturer. This membrane has the
advantage that the Hevin expression can be directly compared
between normal and cancerous tissues from identical patients.
Hevin expression was observed with various levels in all the four
normal tissues tested (Figure 3B, designated N). However, in
cancerous tissues (Figure 3B, designated C), Hevin expression was
down-regulated in colon, rectum and lung by comparison with
those of normal counterparts. No difference was observed in
kidney (Figure 3B). These results (Figure 3A, B) confirm that
Hevin is widely expressed in normal tissues, but its expression is
strongly down-regulated in many cancer cells/tissues.
Hevin is a negative regulator of cell proliferation
The results obtained (Figure 3A,B) suggest that Hevin expression
is strongly down-regulated in a wide range of neoplastic tissues.
However, the physiological meaning of this phenomenon is
unknown. Many genes that inhibit cell growth and differentiation
(e.g. tumour suppressor genes) are also down-regulated in cancer
cells (Bendik et al., 1998). In order to investigate the function of
Hevin on cell growth and differentiation, we have transiently
transfected the Hevin cDNA (M8, see Materials and Methods)
using the tet-off System (Clontech) into HeLa 3S tet-off cells that
lack the endogenous expression of Hevin (see Figure 3A). In this
system, gene expression is turned on when doxycycline (Dox), an
analogue of tetracycline, is removed (Gossen and Bujard, 1992;
Gossen et al, 1995). Unlike other inducible expression systems,
gene regulation in this system is very specific (Gossen et al, 1995).
After the transfection, Hevin expression was verified using RT-
PCR as described in Materials and Methods. Hevin transcript was
clearly observed in the Hevin-transfected cells cultured in the
absence of Dox. In contrast, this transcript was only weakly
detected, if at all, in the cells that were transfected with the expres-
sion vector alone (pTRE) or in Hevin-transfected cells cultured in
the presence of 1 mg ml–1 Dox (results not shown). The rate of cell
proliferation of the cells cultured in the absence of Dox was
measured as described in Materials and Methods. As presented in
Figure 4A, cells transfected with the Hevin clones showed a
reduced level of cell proliferation (average 39.5%, 40.6% and
11.8% reduction in Experiments 1, 2 and 3, respectively) by
comparison with those transfected with the mock vector (pTRE)
alone.
In an effort to further prove the effect of Hevin on cell prolifera-
tion, we created HeLa 3S tet-off cells which were stably transfected
Hevin: a candidate suppressor gene 1127
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Figure 3 Hevin expression is down-regulated in cancer tissues. 
(A) Northern membranes (MNT blots, Clontech) containing 2 mg of poly-A
RNA from the indicated human normal tissues (N1–N3) and cancer cells
(cancer) were hybridized with the radiolabelled human Hevin probe (panel I),
then stripped and reprobed with a human GAPDH probe (panel II). (B)
Northern membranes (mRNA real blots, Invitrogen) containing 2 mg of poly-A
RNA from the indicated human normal (N) and cancer (C) patient-matched
tissues were hybridized with the radiolabelled human Hevin probewith the Hevin clone. Cells were cultured in the absence or pres-
ence of 1 mg ml–1 Dox. Hevin transcript was present in the trans-
fected cells cultured in the absence of Dox. However, this transcript
was only weakly observed in the transfected cells cultured in the
presence of Dox or in the parental cells (results not shown). The
rate of cell proliferation of the cells cultured in the absence of Dox
was measured as described in Materials and Methods. As shown in
Figure 4B, the transfected cells (indicated as Hevin) showed a
reduced level (average 45.2%, 31.4% and 23.5% reduction in
Experiments 1, 2 and 3 respectively) of proliferation by comparison
with the control cells. These results suggest that, as in the transient
expression data (Figure 4A), stably expressed Hevin can reduce the
rate of cell proliferation.
In order to show that the observed effect of Hevin expression on
cell proliferation (Figure 4) is specific and does not arise from
very high (supra-physiological) levels or cytotoxic effects of
Hevin, we measured: (i) levels of Hevin expression by comparison
with those observed in human tissues and (ii) lactate dehydroge-
nase (LDH) from the culture medium as an indicator of cytotoxi-
city (Lagadic-Gossmann et al, 1998). Both in transiently and
stably transfected cells, the level of exogenously expressed Hevin
was not higher than those observed in human omental adipose
tissues by using semi-quantitative RT-PCR (Figure 5).
Furthermore, there was no difference in LDH concentrations in
medium from the cells which do or do not express Hevin (results
not shown). These results argue that the observed negative effect
on cell proliferation (Figure 4, A, B) is caused specifically by the
physiological function of Hevin.
Hevin is involved in the cell cycle regulation
To study the effect of Hevin on cell cycle kinetics, we measured
the proportion of cells in various stages of the cell cycle using
FACScan flow cytometer. Equal numbers of cells that are stably
transfected with Hevin or control cells were reseeded. After 3 days
of culture, the number of the cells that express Hevin was approx-
imately one-third of that of the cells that do not express Hevin
(control), as presented in Table 2. When the distribution in each
phase of the cell cycle was compared, the cells that express Hevin
showed an increased proportion in G0/G1 phase but a reduction in
S phase. In contrast to this, the percentage of G2/M phase was
similar in both cells. This result suggests that Hevin inhibits the
progression of cells from G1 to S phase or prolongs G1 phase.
DISCUSSION
In this work, the human Hevin gene was cloned from human
omental adipose tissue of different patients by RT-PCR and char-
acterized. Sequence examination of our clones have revealed that
they have three nucleotide mismatches with the published Hevin
sequence (GenBank accession No: X82157). These mismatches
cause amino acid changes in protein at positions 116 (S/T), 161
(E/G) and 419 (T/A) (Table 1). However, the changes at 116 aa (T)
and 419 aa (A) were consistently found in five different patients
and may therefore constitute the right sequence for Hevin.
Alternatively, these sequence variations may be adipose tissue-
specific. The variation at 161 aa (E/G) is controversial; out of five
subjects, three had E and the others (two) had G. This mismatch
1128 A Claeskens et al
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Figure 4 Anti-proliferative effect of Hevin. (A) Transient expression. The rate of cell proliferation of transient transfected cells (Hevin and pTRE) was measured
as described in Materials and Methods. The bar graphics represent the mean values obtained from the results of four different wells in each experiment. Values
from the mock (pTRE) transfected cells were taken as 100%. Three independent experiments (Exp 1, Exp 2 and Exp 3) are presented. (B) Stable expression.
The rate of cell proliferation of stable transfected or parental cells was measured as described in Materials and Methods. The bar graphics represent the mean
values obtained from the results of four different wells in each experiment. Values from the parental cells were taken as 100%. Three independent experiments
(Exp 1: 1000 cells per well cultured for 96 h, Exp 2: 2000 cells per well cultured for 96 h, Exp 3: 5000 cells per well cultured for 48 h) are presentedmay be due to a polymorphism of the Hevin gene at this position.
However, we cannot rule out the possibility that these changes are
caused by PCR mutations in spite of the fact that proof-reading
Taq polymerase was used. However, these sequence variations do
not lie in one of the potential functional domains of Hevin (trans-
membrane, acidic, follistin-like, or calcium binding domains)
(Girard and Springer, 1995). Thus it is unlikely that these
mismatches will affect the function of Hevin. To this end,
sequence determination by screening different cDNA libraries
could clarify the nature of these sequence variations. Alternatively,
screening of meiosis (Lynch et al, 1995; Taylor et al, 1998) will
determine whether these variations may be real polymorphisms.
We have further produced Hevin protein by in vitro translation
in reticulocyte lysate and its protein appearance was determined by
SDS-PAGE (Figure 1). The calculated Mr of Hevin is 75 kDa.
However, in addition to this signal, we have observed a 150 kDa
signal. We therefore speculate that Hevin may form a homodimer
in vitro. Indeed, Girard and Springer (1996) also observed that the
Mr 75 kDa Hevin migrated at a molecular weight of 130 kDa.
Thus, homodimerization, a common theme for cell surface recep-
tors, appears to explain the retained molecular mobility of Hevin.
It remains to be tested whether Hevin forms a homodimer in vivo.
Based upon the Northern blots (Figure 3 A,B), Hevin was found
to be expressed in a wide range of normal or non-neoplastic
tissues, although with varying degrees. Conceivably, this high
abundance in different tissues may indicate a more general non-
tissue-specific role of Hevin. However, considering the tissue-
specific degrees of expression (Figure 3 A,B), Hevin may play a
more prominent role in tissues with high levels of expression (e.g.
heart, skeletal muscle, small intestine, spinal cord; see Figure 3A).
Initially, we cloned this gene from fat (omental adipose) tissues
and we are currently interested in investigating the functional role
of Hevin in adipogenesis and/or fat metabolism. Through the
human EST database analysis (Incyte Pharmaceuticals, Palo Alto,
CA, USA), Hevin ESTs were found at high frequency in inflam-
matory diseased tissues in artery and uterus, suggesting that Hevin
may be involved in the inflammatory process (results not shown).
In contrast to this, Hevin expression is strongly down-regulated
in cancer cell lines (Figure 3A) or in cancer tissues by comparison
with matching normal tissues (Figure 3B). The mechanisms that
cause this inactivation of its expression in neoplastic tissues have
yet to be clarified. At least two hypotheses can be postulated for
this down-regulation. One possibility is that the Hevin gene is
deleted or mutated in cancer cells. Another possibility is that the
gene is intact but its expression is impaired. Genetic and gene
regulation studies are required in order to answer these questions.
The fact that the Hevin expression is down-regulated in neoplastic
tissues could be useful for diagnostic purposes. Furthermore, it is
of interest to investigate at which stage of the cancer process this
down-regulation occurs. This information will enhance diagnosis
or determination of the staging of cancers.
Many genes responsible for tumorigenesis, for example, onco-
genes and tumour suppressor genes, show a differential expression
pattern between normal and neoplastic tissues. Some of these
genes were cloned using this differential expression property
(Nakshatri et al, 1996; Panotopoulou et al, 1997; Bendik et al,
1998). The tumour suppressor genes (or anti-oncogenes) are nega-
tive regulators of cell proliferation. They do so by regulating DNA
synthesis, cell cycle checkpoints or apoptosis (Weinberg, 1995).
Their expression and function are frequently lost in cancers
(Weinberg, 1996). Due to the loss of expression of Hevin in cancer
cells/tissues (Figure 3), we postulate that it may be a novel candi-
date tumour suppressor gene. Loss of function of tumour
suppressor genes plays a central role in the development of cancer.
The characterization of the biochemical pathways by which
tumour suppressor alteration triggers tumorigenesis is the
foundation for the design of novel therapeutic approaches (Fulci et
al, 1998). Indeed, p53, the best studied tumour suppressor gene,
has been successfully used in a gene therapy approach to cancer
treatment and efforts are also being made to restore the p53 func-
tion using small molecules (reviewed in Chen and Mixson, 1998).
To investigate the functional role of Hevin in cell growth and
differentiation, we expressed this gene transiently and stably using
a tetracycline inducible expression vector (pTRE, Gossen et al,
1995) to the cells that lack endogenous expression of Hevin, and
we measured the rate of proliferation (Figure 4 A,B). We were able
to demonstrate that Hevin, in analogy to SPARC, is a negative
regulator of cell proliferation. Further, we have shown that Hevin
can inhibit the progression of cells from G1 to S phase (Table 2).
To the best of our knowledge, this is the first report describing the
effect of Hevin in cell growth and differentiation. This observation
further supports our hypothesis that Hevin is a tumour suppressor
gene. Tumour suppressor genes are known to inhibit cell growth
and differentiation by regulating the entry of cells into the cell
cycle, arresting the cell cycle progression, initiating programmed
cell death (apoptosis). The detailed functional analysis of Hevin on
those issues will be required for a better understanding of this
gene. Loss of heterozygosity (LOH) analysis has been used in
many types of human cancer to localize putative tumour
suppressor genes. Through database analysis (National Center
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Table 2 Effect of Hevin on HeLa cell cycle progression
Distribution of cells (%)
Total cellsa
Cell phase G0/G1 S G2/M (% control)
Control 52.3 30.5 16.9 100
Hevin 62.1 22.8 15.2 27
A total of 0.3 ´ 106 cells were grown for 72 h in 75-cm2 flasks in the absence
of Dox. Cell cycle measurements were performed as described in Materials
and Methods. The given percentage corresponds to the mean of two
samples. The experiment was repeated twice with similar results. aAfter 3
days, 2 ´ 106 cells are found in the control cultures.
Figure 5 Levels of Hevin expression in tet-off system and intact human
tissue. RNAs were prepared from transiently (T) and stably (S) transfected
HeLa 3S tet-off cells and human omental white adipose tissue (HWAT).
Levels of Hevin expression were compared by quantitative RT-PCR using the
Hevin-specific primer. GAPDH was used as a controlBiotechnology Information, Gene Map), Hevin was mapped to
chromosome 4. This chromosome has been shown to contain hot
spots for LOH in many cancers (Obata et al, 1997; Radany et al,
1997; Ritland et al, 1997; Asamoto et al, 1998; Santos et al, 1998).
This genetic approach again supports the notion that Hevin may be
a tumour suppressor gene. Recently some tumour suppressor
genes (e.g. APC, NF-2 and VHL) have been shown to be involved
in cell–cell adhesion (Hirohashi, 1998; Ohh et al, 1998; Shaw et al,
1998). Proper cell–cell adhesion and communication are essential
for normal cell growth and are often perturbed during cancer
formation. Hevin, an anti-adhesive extracellular matrix protein,
may exert its anti-proliferative effect through interference with
cell–cell adhesion. In order to determine the physiological role of
Hevin in vivo, and to further prove that it is indeed a tumour
suppressor gene, it is particularly important to create a knock-out
model of the Hevin gene. Ultimately, understanding Hevin at a
molecular level and in vivo may uncover potential approaches for
the treatment and diagnosis of cancers in humans.
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